Bharat Parenterals Ltd
BSE:541096
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (47.3), the stock would be worth ₹-3 554.94 (394% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.1 | ₹1 208.65 |
0%
|
| Industry Average | 47.3 | ₹-3 554.94 |
-394%
|
| Country Average | 35.9 | ₹-2 696.02 |
-323%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
B
|
Bharat Parenterals Ltd
BSE:541096
|
8.3B INR | -16.1 | -102.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 153.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 29.4 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 26.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 40.8 | 28.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 24.5 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 19.6 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 1 486.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 44.5 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 22 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 12 | 17.3 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 20.7 |
| Median | 35.9 |
| 70th Percentile | 64.8 |
| Max | 50 585.9 |
Other Multiples
Bharat Parenterals Ltd
Glance View
Bharat Parenterals Ltd. engages in the manufacture of pharmaceutical formulations. The company is headquartered in Vadodara, Gujarat. The company went IPO on 2018-03-21. The firm is engaged in research, development, manufacturing, marketing, sourcing and distribution of pharmaceutical products. The firm offers a range of products, including B-lactam antibiotics, anti-retroviral, cephalosporins antibiotics, antiprotozoal / anthelmintic, respiratory, antiallergic / anti histaminic / anticold, cleansing agents/skin infections, antibiotic, cardiovascular system, anti-diabetic, anti-tuberculosis, anti-fungal, antimalarial, gastroinestinaltract / alimentary system, anti-inflammatory / anti pyretic / analgesic, supplements, central nervous system, anesthetics, anti-viral, steroids and hormones, uterine stimulant, anticancer and other.
